A U.S.-based medical device company specializing in advanced products for the cardiac electrophysiology market Catheter Precision, Inc. (NYSE: VTAK), has reported strong second-quarter results, marked by significant revenue growth, key regulatory milestones, and the presentation of notable clinical data.
In te second quarter, revenue from product sales rose 128% year-over-year to approximately $212,000, compared to $93,000 in the same period of 2024. Sequentially, revenue climbed 48% from the previous quarter. First-half 2025 revenue increased 103% to approximately $355,000 from $175,000 in the first half of 2024.
The company also achieved an important regulatory milestone during the quarter, securing CE Mark approval for its LockeT product, with sales expected to begin in Europe in the third quarter of this year.
Clinical momentum was bolstered by multiple presentations at the annual Heart Rhythm Society symposium, showcasing data that underscored the accuracy, safety, and efficacy of Catheter Precision’s technologies. These included a multi-center registry study demonstrating that VIVO, the company’s non-invasive cardiac mapping system, achieved over 94% accuracy and may improve long-term outcomes when used pre-procedure. Other studies highlighted VIVO’s ability to enhance mapping for complex premature ventricular contractions (PVCs), its precision in scar-dependent ventricular tachycardia (VT) mapping, and LockeT’s safety and effectiveness in large-bore access electrophysiological procedures.
The quarter also saw strategic advancements, including the acquisition of heart failure assets from Cardionomic through Cardionomix, an 82%-owned subsidiary, and the formation of Kardionav, Inc., a majority-owned joint venture developing an implant-based software product aimed at treating ventricular tachyarrhythmia.
Catheter Precision reported total assets of $25.6M, shareholders’ equity of $6.5M, and a cash position of $838K. The company posted a net loss of approximately $5.4 million for the quarter, including $3.2M in non-cash charges, and a net loss of approximately $9.5M for the first half, including $4.4M in non-cash charges.
David Jenkins, CEO of Catheter Precision, commented, “We are extremely excited about our results on all fronts: increasing sales, strong clinical data, and execution of strategic transactions with a goal of increasing the future value of Catheter Precision. We are seeing increased awareness and desire for our products, both here in the US, and now, with the CE Mark for the LockeT in Europe, internationally as well. The team is energized with our progress, and we are looking forward to our results in the coming quarters.”
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Catheter Precision Reports 128% Year-Over-Year Revenue Growth in Q2, Advances Clinical and Strategic Initiatives appeared first on PRISM MarketView.
